Human Longevity
PrivateLast Round
Series B
Aug 21, 2024
Est. Valuation
$185.79M
Total Funding Raised
$399.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Human Longevity operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in August 2024.
Human Longevity is a biotechnology company that offers a platform integrating genomic and phenotypic data to enhance the understanding of human health and proactively address age-related health issues through advanced DNA sequencing and machine learning.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical Imaging, Healthcare Analytics, Medical AI
Business Model
B2C
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Human Longevity Comparables
Compare Human Longevity with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biograph | 88% | |
| Fountain Life | 87% | |
| Prenuvo | 87% |
For institutional investors. Book with your work email.
Human Longevity Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 21, 2024 | ||||
| M&A | Dec 28, 2022 | ||||
| Series A-2 | Nov 6, 2019 | ||||
| Series C | Dec 4, 2018 | ||||
| Series B | Apr 4, 2016 | ||||
Series A | Jun 1, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Human Longevity Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Emerging Technology Partners | Series B, Series C |
| Threshold Ventures | Series A |
| OS Fund | Series B, Series A |
| TVM Capital Healthcare | Series B |
| BBRC Worldwide | Series A |
| Panacea Venture Healthcare | Series B, Series C |
| GE Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2026
Partnership with the Buck Institute disclosed in job posting.
- Jul 1, 2026
Job posting reveals collaboration with Nucleus Medical Group.
For institutional investors. Book with your work email.
Human Longevity Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Human Longevity's valuation, stock price, and market status.
Is Human Longevity a public or private company?
Human Longevity is a private company.
What is the current stock price of Human Longevity?
Human Longevity is a private company, so its shares have no public market price. Caplight tracks Human Longevity's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Human Longevity worth (valuation)?
Human Longevity's valuation is estimated at $185.8M based on funding round data.
Can I buy Human Longevity stock?
Human Longevity shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Human Longevity's last funding round?
Human Longevity's most recent funding round was Series B on August 21, 2024.
Who are the main investors in Human Longevity?
Key investors in Human Longevity include Emerging Technology Partners.
Will Human Longevity IPO soon?
No public IPO plans have been announced for Human Longevity.
How can I track Human Longevity secondary market activity?
Caplight tracks bids, offers, and trades in Human Longevity's shares on secondary markets.